Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

Christopher Em Griffiths; Bruce Strober; Peter van de Kerkhof; Vincent Ho; Roseanne Fidelus-Gort; Newman Yeilding; Cynthia Guzzo; Yichuan Xia; B. Zhou; Shu Li; Lisa T. Dooley; Neil Goldstein; Alan Menter

doi:10.1056/nejmoa0810652

Abstract

1 min read

The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis. (ClinicalTrials.gov number, NCT00454584.)

Related publications

Article2008

Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study

Jean‐Paul Ortonne, Christopher Em Griffiths, E. Daudén, Robert Strohal, Deborah Robertson, Ronald Pedersen, C. Molta, Bruce Freundlich

Article2010

Comparing biological therapies in psoriasis: implications for clinical practice

Christopher Em Griffiths

Article2020

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp

Article2013

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Kim Papp, Christopher Em Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, M.-C. Hsu, Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich

Article2009

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

Catherine Smith, A.V. Anstey, Juliet N. Barker, A. David Burden, R.J.G. Chalmers, David Chandler, A.Y. Finlay, Christopher Em Griffiths, Karina Jackson, N. McHugh, Kevin E. McKenna, Nick J. Reynolds, Anthony D. Ormerod